For Business Use Only. Does Not Ship to Residential Addresses. For use inside an Analyzer, Sold Separately.
Helena Factor VIII (10x1mL)
- Lower your cost per test.
- Get your real time pricing options within 60 minutes.
- Trade in your old analyzers to recover budget.
- Bundle equipment, reagents, consumables into one cost-saving order.
- Enlist our nationwide service to keep uptime high.
Meet your sales rep Ben Morton, covering your area.
Would you like to book 15 minutes on Ben Morton's calendar to get the best value for your budget?
Yes, book the timeIn Stock
Product code: 5193
MPN: 5193
Manufacturer: Helena Laboratories
Shipping Weight: 25.00lbs (11.34kg)
Factor VIII (10x1mL)
Factor VIII Deficient Substrate, 10 x 1 mL
Intended Use
The Factor VIII Deficient Substrate Plasma is intended for the quantitative determination of Factor VIII (antihemophilic factor) in patients suspected of having a congenital or acquired deficiency of this coagulation protein.
Summary
Numerous coagulation factors have been identified in the blood and are required for normal blood clotting. A deficiency of one or more of the factors may result in a notable hemorrahagic condition, the severity of which is governed by the degree of the deficiency. Deficiencies of the blood clotting factors may be congenital or acquired. The congenital deficiencies are, in general, single deficiency states while the acquired deficiencies may be multiple in nature and commonly associated with liver disease, vitamin K deficiency or the ingestion of coumarin type anticoagulant drugs, and defibrination secondary to intravascular clotting.
Factor VIII, known as antihemophilic factor (AHF) or antihemophilic globulin (AHG), is decreased in two congenital diseases, Hemophilia A or “classical hemophilia” which is a sex linked recessive trait, and von Willebrand’s disease, which is an autosomal dominant trait. In an effort to devise a quantitative assay for Factor VIII, several methods based on the thromboplastin test were used and were found to be time consuming and complicated. Langdell, Wagner and Brinkhous (1953) developed a one stage “partial thromboplastin time” which was simple to perform but not reproducible. Helena’s procedure determines Factor VIII activity by using a modification of the activated partial thromboplastin time (APTT) test and a Factor VIII deficient substrate plasma.
